LoadingLoadingLoadingNet selling: insiders sold $17M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Millennium
$53.6M
added
Sells/Trims (2)
Stanley Druckenmiller
$50.4M
trimmed
Glenview Capital
$321.2M
trimmed
Top-trader positions in TEVA could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 29, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.05 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$0.60 to $0.89
Revenue expected
11 analysts
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $0.64 / $0.05Alpha Vantage | +$0.59 beat | $4.14B No estimate | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | $0.53 / $0.46Alpha Vantage | +15.22% beat | $3.98B No estimate | Unavailable |
| Dec 31, 2025 | Jan 28, 2026 | $0.96 / $0.64Alpha Vantage | +50.00% beat | $4.71B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $0.75 / $0.66Alpha Vantage | +13.64% beat | $4.48B No estimate | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | $0.66 / $0.62Alpha Vantage | +6.45% beat | $4.18B No estimate | Unavailable |
| Mar 31, 2025 | May 7, 2025 | $0.52 / $0.46Alpha Vantage | +13.04% beat | $3.89B No estimate | Unavailable |
| Dec 31, 2024 | Jan 29, 2025 | $0.71 / $0.70Alpha Vantage | +1.43% beat | $4.23B No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $0.69 / $0.66Alpha Vantage | +4.55% beat | $4.33B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.48B | $4.71B | $3.98B | $4.14B |
| Cost of what it sold | $2.18B | $2.06B | $2.01B | $1.99B |
| Gross profit | $2.30B | $2.66B | $1.97B | $2.15B |
| What it spent | ||||
| Research and development | $256.0M | $267.0M | $222.0M | $250.0M |
| Sales and admin | $317.0M | $367.0M | $304.0M | $317.0M |
| Other operating costs | $849.0M | $1.72B | $792.0M | $1.44B |
| Total operating expenses | $1.42B | $2.35B | $1.32B | $2.00B |
| What was left | ||||
| Operating profit | $882.0M | $300.0M | $652.0M | $149.0M |
| Interest on debt | $209.0M | $292.0M | $201.0M | $200.0M |
| Profit before tax | $648.0M | $91.0M | $436.0M | -$455.0M |
| Tax | $214.0M | -$390.0M | $67.0M | $121.0M |
| Net profit | $433.0M | $480.0M | $369.0M | -$576.0M |
| EBITDA | $1.10B | $632.0M | $877.0M | -$19.0M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Teva Pharmaceutical Industries Ltd. Tokenized Stock (Reality) (RTEVA) Price Prediction for 2026 to 2031
NeutralOct 20UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
NeutralOct 20Teva Pharmaceutical Industries (TEVA) Gets FDA Nod For Monthly Schizophrenia Injection
BullishOct 18TEVA Maintained by Barclays -- Price Target Raised to $47.00
Leans bearishOct 15Teva Pharmaceutical Industries (NYSE:TEVA) Given New $47.00 Price Target at Barclays
BullishOct 15Teva to Host R&D Day on Wednesday, November 11 in New York City
Leans bullishOct 13Teva to Host R&D Day on Wednesday, November 11 in New York City
Leans bullishOct 12Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026
NeutralOct 12